The accelerated approvals of Kymriah (Novartis) for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and Yescarta (Kite Pharma, a Gilead company) for relapsed/refractory large B-cell lymphoma herald a new era in cancer immunotherapy. In this series of reports, we present a comprehensive analysis of current and emerging chimeric antigen receptor (CAR) T-cell therapies. We examine the CAR T-cell treatment landscape: the technology behind it, ongoing clinical development, the challenges, pricing and market access, physicians’ views, and future opportunities for this paradigm-shifting treatment approach.


  • How is CAR T-cell therapy being adopted into medical practice? What kind of referral patterns are in place for potentially eligible patients? What is the typical patient journey for a patient receiving CAR T-cell therapy?
  • What kind of support and training programs for Kymriah and Yescarta are in place for healthcare professionals, patients, and caregivers?
  • What are the key pricing, access, and reimbursement issues facing Kymriah and Yescarta? What novel reimbursement strategies are marketers implementing to ensure market access?
  • What challenges remain and could limit widespread and maximum adoption of autologous CD19-targeted CAR T-cell therapies? What are the future directions and opportunities?
  • What are the notable developments in the pipeline? Who are the key players, and what novel targets are they exploring?


Special Topics Report Series: Is a three-wave series based on KOL interviews conducted at about one, six, and twelve months postcommercialization and on secondary data collected from a variety of sources. We capture physicians’ awareness, perception, and use of the launched product and anticipated future trends.

Markets covered: United States

Primary research: Qualitative interviews with ten U.S. hematologist-oncologists and thought leaders for the three waves.

Key metrics included:

  • Physician familiarity with and impressions of Kymriah, Yescarta, and other CAR T-cell therapies in the pipeline.
  • Referral patterns, patient journey, and certification of treatment centers.
  • Current manufacturing and scalability challenges.
  • Marketing and educational programs for patients, healthcare professionals, and caregivers.
  • Cost of CAR T-cell therapy and novel pricing and market access strategies.

Table of contents

  • Chimeric Antigen (CAR) T-Cell Therapy - Special Topics - US (Wave 3)
    • Executive Summary
      • Executive Summary
      • Expert Insight
    • The CAR T-Cell Therapy Paradigm
      • The CAR T-Cell Therapy Paradigm
    • Kymriah (Tisagenlecleucel-T)
      • Kymriah (Tisagenlecleucel-T)
      • Support and Training Programs for Kymriah
      • Pricing, Access, and Reimbursement for Kymriah
      • Ongoing Clinical Development of Kymriah
    • Yescarta (Axicabtagene Ciloleucel)
      • Yescarta (Axicabtagene Ciloleucel)
      • Support and Training Programs for Yescarta
      • Pricing, Access, and Reimbursement for Yescarta
      • Ongoing Clinical Development of Yescarta
      • Choosing Between Kymriah and Yescarta
        • Physicians' Choice Between Kymriah and Yescarta
    • CAR T-Cell Therapy Pipeline
      • Notable Developments in the Pipeline
    • Challenges and Future Directions
      • Challenges Facing Current CD19-Targeted CAR T-Cell Therapies
      • Future Directions and Opportunities for CAR T-Cell Therapies
    • Methodology
      • Primary Market Research
        • Primary Market Research
    • Appendix
      • CAR T-Cell Therapy Bibliography

Author(s): Ed Cortellini

Ed Cortellini is a Business Insights Analyst in the Oncology group at Decision Resources ; He joined DRG in January 2012 as a Data ; He has produced quantitative & statistical analysis across all DRG products which include but are not limited to unmet needs, current treatment, access and reimbursement, patient profiler, and emerging therapies.